Therapeutic potential of lipase inhibitor orlistat in Alzheimer's disease
Therapeutic potential of lipase inhibitor orlistat in Alzheimer's disease
复制标题
DOI：
10.1016/j.mehy.2009.04.046
复制
发表时间：
2009-11-01
影响因子：
4.7
通讯作者：
Wang, Zhao
中科院分区：
文献类型：
--
作者：
Du, Jing;Wang, Zhao
新出现的证据表明，胆固醇和甘油三酯水平升高先于阿尔茨海默病（AD）的病理。基于饱和脂肪的高热量摄入会引起糖尿病，也会促进AD病理学。因此，限制膳食脂肪吸收和降低高脂血症的策略可能是AD保护性治疗的有用药物。奥利司他作为一种活性的消化脂肪酶定点抑制剂，可有效减少膳食脂肪吸收，降低血浆中总胆固醇和甘油三酯水平。奥利司他还有效抑制脂蛋白脂肪酶、单酰基甘油脂肪酶和二酰基甘油脂肪酶，这些也参与AD的病因。综上所述，奥利司他抑制脂肪酶活性，从而减少膳食脂肪摄入并改善高脂血症，这表明奥利司他在预防AD病理学方面的治疗潜力。(C)2009爱思唯尔有限公司保留所有权利。
Emerging evidences indicate that elevated cholesterol and triglyceride levels precede Alzheimer's disease (AD) pathology. High caloric intake based on saturated fat raises hyperlipidaemia and also promotes AD pathology. As a result, strategy that limits the absorption of dietary fat and attenuates hyperlipidemia could be a useful medication for protective treatment of AD. As an active site-directed inhibitor of digestive lipases, orlistat effectively reduces dietary fat absorption and decreases total cholesterol and triglyceride levels in plasma. Orlistat also potently inhibits lipoprotein lipase, monoacylglycerol lipase and diacylglycerol lipase, which are also involved in AD causation. Taken together, orlistat inhibits lipases activities, thereby reduces dietary fat intake and ameliorates hyperlipidemia, which indicates a therapeutic potential of orlistat in protecting against AD pathology. (C) 2009 Elsevier Ltd. All rights reserved.